2 news items
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
CNTB
22 May 24
benefit, improvement, differentiation, trend or profile or any product approval or be effective, the Company's ability to identify and enter into any
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
CNTB
16 Apr 24
in December 2023 on the Phase 2 trial of icanbelimod showing that patients with UC would likely derive greater clinical benefit with higher doses than
- Prev
- 1
- Next